ClinicalTrials.gg
Enrolling by invitationNCT06605677Updated Sep 26, 2024

Knowledge Attitude and Practice Regarding Bloodstream Bacterial Infections and Antibiotics Usage Among Doctors.

An observational study in Bacteremia, Antimicrobial Stewardship and Antibiotic Use, sponsored by Abu Dhabi Health Services Company. Enrolling by invitation at 1 site in United Arab Emirates. Per ClinicalTrials.gov, last updated 2024-09-26.

Sponsored by Abu Dhabi Health Services Company · Observational

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as enrolling by invitation.
Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
100
Sex
All
01

Study summary

This study is designed to use a questionnaire to assess doctors' knowledge, attitudes, and practices regarding bloodstream bacterial infections and antibiotic use in Tawam and Al Ain tertiary Hospitals (both hospitals have the same medical team) in Al Ain City, UAE.

Read the detailed description

Background: Bloodstream bacterial infection is a serious medical problem and one of the leading causes of death worldwide among all age groups. Appropriate and early antibiotic use has been associated with better outcomes based on many clinical trials. On the other hand, misuse and abuse of antibiotics have been linked to long hospital stays, significant morbidity and mortality, increased medical costs and rising antimicrobial resistance (AMR). Statistics in hospitals involved in the study, showed increased antibiotic consumption compared to previous years and other regional healthcare facilities. Rates of AMR in the UAE have increased significantly in the last decade, based on the 2022 annual report.

Aims and objectives This study will assess knowledge, attitude and practice regarding bloodstream bacterial infections and antibiotics use among doctors. It is a questionnaire-based cross-sectional descriptive study that will be conducted at Tawam and Al Ain Hospitals (tertiary hospital, both hospitals have the same medical team).

The investigators want to explore the degree of knowledge and attitude, assess the appropriate usage of antibiotics among doctors in different subspecialties, assess any possible barriers, and find solutions such as medical education for this challenging medical problem.

02

Conditions studied

  • Bacteremia
  • Antimicrobial Stewardship
  • Antibiotic Use
  • Antibiotic Abuse

Browse trials for

Keywords

  • bacteremia
  • antimicrobial resistance
  • antimicrobial stewardship
  • healthcare workers
  • antibiotic use
  • antibiotic abuse
03

In context

Bacteremia

297 studies on the registry are indexed under Bacteremia; 51 are open to participants now.

This study's planned enrollment of 100 is below the median of 300 across 125 observational studies indexed under Bacteremia.

Browse Bacteremia studies →

Lead sponsor

Abu Dhabi Health Services Company is the lead sponsor of 9 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Licensed, practicing physicians, multinational

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All physicians with valid medical licenses working in Tawam and Al Ain tertiary hospitals

Exclusion criteria

Exclusion Criteria:

Infectious diseases physicians and Microbiologists

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • All doctors with valid medical license in Tawam and Al Ain Hospitals

    The group excludes infectious disease physicians and microbiologists.

    Other: Questionnaire

Interventions

  • OtherQuestionnaire

    An online questionnaire will be sent through e-mail to participants. It is divided into 4 sections: demography and general information 9 questions, knowledge 10 questions, attitude 10 questions and practice 10 questions. No previous similar studies were conducted in the United Arab Emirates (UAE) or internationally based on a search in PubMed and Cochrane library. Hence a validated questionnaire is lacking. Therefore, the questionnaire for this study is designed based on questions encountered daily by colleagues during the consultation, and it can serve the purpose of this study. Consent will be obtained and signed electronically by participants before starting the questionnaire. Participation involves minimal risk. Responses will be anonymous and confidential. Participants' involvement is voluntary, and they can withdraw at any time without any consequences. The time to complete the questionnaire is around 10-15 minutes. Each response will be saved using a unique identifier number.

06

What researchers measure

Primary outcomes

  1. Understanding physician knowledge on antibiotic use in bacterial bloodstream infections (bacteremia).

    Questions to assess physicians' knowledge related to basic microbiology, bacterial infections and antibiotic spectrum of activity using dichotomous questions; yes/no.

    Time frame: 1 year

  2. Understanding physician attitude on antibiotic use in bacterial bloodstream infections (bacteremia).

    Questions to assess physicians' attitude in bacteremia management using dichotomous questions; yes/no, Likert scale or multiple choices.

    Time frame: 1 year

  3. Understanding physician practices on antibiotic use in bacterial bloodstream infections (bacteremia).

    Questions to assess physicians' practice in bacteremia management using dichotomous questions; yes/no, or multiple choices.

    Time frame: 1 year

07

Study locations

1 site
  • Tawam and Al Ain Hospital
    Al Ain, United Arab Emirates
08

References and documents

Publications

  • Thomsen J et al. United Arab Emirates Surveillance of Antimicrobial Resistance Annual Report 2022.
  • Labelle A, Juang P, Reichley R, Micek S, Hoffmann J, Hoban A, Hampton N, Kollef M. The determinants of hospital mortality among patients with septic shock receiving appropriate initial antibiotic treatment*. Crit Care Med. 2012 Jul;40(7):2016-21. doi: 10.1097/CCM.0b013e318250aa72. PubMed 22584765 ↗
  • Zahar JR, Timsit JF, Garrouste-Orgeas M, Francais A, Vesin A, Descorps-Declere A, Dubois Y, Souweine B, Haouache H, Goldgran-Toledano D, Allaouchiche B, Azoulay E, Adrie C. Outcomes in severe sepsis and patients with septic shock: pathogen species and infection sites are not associated with mortality. Crit Care Med. 2011 Aug;39(8):1886-95. doi: 10.1097/CCM.0b013e31821b827c. Erratum In: Crit Care Med. 2011 Oct;39(10):2392. Vesim, Aurelien [corrected to Vesin, Aurelien]. PubMed 21516036 ↗
  • Kreger BE, Craven DE, McCabe WR. Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med. 1980 Mar;68(3):344-55. doi: 10.1016/0002-9343(80)90102-3. PubMed 6987871 ↗
  • Bearman GM, Wenzel RP. Bacteremias: a leading cause of death. Arch Med Res. 2005 Nov-Dec;36(6):646-59. doi: 10.1016/j.arcmed.2005.02.005. PubMed 16216646 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06605677
Lead sponsor
Abu Dhabi Health Services Company
Responsible party
Noura Saif Alnuaimi (Consutant Physician_ Internist, Abu Dhabi Health Services Company) — Principal investigator
First posted
Sep 20, 2024
Start date
Sep 9, 2024
Primary completion
Mar 9, 2025 (estimated)
Completion
Mar 9, 2025 (estimated)
Last update
Sep 26, 2024

Study contacts

Noura Saif Alnuaimi, MD
principal investigator · Abu Dhabi Health Services Co-SEHA
Ahmed Al Hammadi, MD
study chair · Abu Dhabi Health Services Co-SEHA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion